Inovio Pharmaceuticals is trading 5.6% down at $1.18, primarily as biotech stocks weakened broadly during the September 24, 2026 session.
- XBI fell 2.04%, while higher Treasury yields and renewed inflation concerns pressured growth-oriented healthcare shares.
- Trading was during regular market hours; no fresh company-specific announcement was identified. Broader markets were also under pressure as the 10-year Treasury yield reached approximately 5.14%.
- The October 30 FDA decision for INO-3107 remains the key company catalyst.